Trial Profile
Comparative Efficacy of DuodartTM Versus Watchful Waiting With Step-up Therapy to Tamsulosin in the Management of Treatment naïve Men With Symptomatic BPH
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Dutasteride (Primary) ; Tamsulosin
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Acronyms CONDUCT
- Sponsors GlaxoSmithKline; GSK
- 28 Nov 2020 Results of pooled meta-analysis from six clinical studies: ARIA3001, ARIA3002, ARI40002, ARIB3003, CombAT and CONDUCT published in the British Journal of Clinical Pharmacology
- 26 Jul 2020 Results (n=10238) of pooled analysis of 6 studies (ARIA3001, ARIA3002, ARI40002, ARIB3003, CombAT, CONDUCT) assessing impact of early vs delayed initiation of dutasteride/tamsulosin combination therapy in benign prostatic hyperplasia patients with moderate to severe lower urinary tract symptoms, presented at the 35th Congress of the European Association of Urology.
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.